Oncology
Refine search
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Pharmaceutical
Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Biotechnology
UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. 13 April 2026
Biotechnology
Chinese clinical-stage biotech OriCell Therapeutics announced the cumulative closing of a pre-initial public offering (IPO) financing round in excess of $110 million. 13 April 2026
Biotechnology
US biotech Replimune has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower and casting doubt over the program’s future. 13 April 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved a label update for Ferring’s Adstiladrin (nadofaragene firadenovec-vncg), enabling an accelerated water-bath thawing method, completed in about 25 minutes, to enhance efficient clinical preparation for healthcare teams. 25 March 2026
Pharmaceutical
Norwegian bladder cancer specialist Photocure and its Chinese partner Asieris Pharmaceuticals have announced that Cevira (hexaminolevulinate hydrochloride ointment photodynamic therapy system) was included in the joint expert consensus of four prestigious medical societies in China. 25 March 2026
Pharmaceutical
San Diego, USA-based Yatiri Bio, an AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor, for the treatment of acute myeloid leukemia (AML). 25 March 2026
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Keytruda (pembrolizumab), within its marketing authorization, for patients identified for surgery with resectable, locally advanced head and neck squamous cell carcinoma (LA HNSCC), whose tumors express PD-L1 with a combined positive score (CPS) of at least one. 24 March 2026
Biosimilars
Singapore-based biotech Prestige Biopharma has reported positive Phase III results for its Avastin (bevacizumab) biosimilar HD204 in advanced non-squamous non-small cell lung cancer. 24 March 2026
Pharmaceutical
Karyopharm Therapeutics today reported top-line results from its Phase III SENTRY Trial in myelofibrosis that met the first co-primary endpoint, demonstrating statistically-significant improvement in spleen reduction volume. 24 March 2026
Pharmaceutical
.Swiss pharma major Novartis is committing more than 3.3 billion yuan ($480 million) to expand its footprint in China, deepening a strategic shift toward local innovation and manufacturing as the country cements its role as a key growth engine. 24 March 2026
Biotechnology
Damora Therapeutics, a US biotech with the stated ambition of fundamentally redefining care for patients with blood disorders, has appointed Jennifer Jarrett as president and chief executive. 24 March 2026
Biotechnology
Taiwan-based GlycoNex, a biotech developing glycan-directed cancer immunotherapies, has entered into a collaboration agreement with Japan’s Nippon Kayaku to advance GNX201-ADC, a next-generation antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. 23 March 2026
Biotechnology
Anaveon, a late-stage Swiss pre-clinical biotech focused on reprogramming the immune system with precision biologics, today announces the appointment of Thaminda Ramanayake as its new chief executive (CEO). 23 March 2026
Biotechnology
AI-driven biotech Earendil Labs has secured $787 million in financing to expand its biologics pipeline and internal R&D capabilities, with backing from Sanofi and a biotech fund created by Pfizer, among others. 23 March 2026
Pharmaceutical
Significant research news last week included US biotech CytomX Therapeutics releasing positive new data on its colorectal cancer candidate varsetatug masetecan (VarsetaM). Pfizer reported encouraging data on its investigational breast cancer drug atirmociclib, which could be a successor for its Ibrance, and Eli Lilly posted new Phase III data on its diabetes candidate retatrutide. Also of note, Johnson & Johnson and Protagonist’s gained US Food and Drug Administration (FDA) approval for their plaque psoriasis drug Icotyde (icotrokinra). 22 March 2026
Pharmaceutical
Japanese drugmaker Eisai has announced that the administration of the anticancer agent EZH2 inhibitor Tazverik tablets 200mg (tazemetostat hydrobromide), which is manufactured and marketed in Japan by Eisai should be discontinued.]- 21 March 2026
Biotechnology
Adding to the growing list of newcomers to the fast-growing obesity and metabolic disease space, privately-held Endevica Bio has spun out Illinois, USA based biotech Kalohexis. 19 March 2026
Pharmaceutical
US pharma giant Pfizer has announced positive topline results from the Phase III TALAPRO-3 study. 19 March 2026
Pharmaceutical
German biotech Evotec said partner Bristol Myers Squibb has begun a Phase I trial of BMS-986506 in clear cell renal cell carcinoma, marking the first clinical milestone from their long-running protein degradation collaboration. 19 March 2026
Biotechnology
Cambridge, USA-based biotech Crossbow Therapeutics, which is developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, today announced it has raised $77 million in a Series B financing. 19 March 2026
Biotechnology
UK-based Amphista Therapeutics, a self-styled leader in the discovery and development of next generation targeted protein degradation (TPD) medicines, has announced a personnel change at the top of the company. 18 March 2026
Biotechnology
Shanghai, China-based biotechnology Excalipoint Therapeutics, which is developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases, today announced an oversubscribed $68.7 million seed financing round to support advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programs. 18 March 2026
Biotechnology
German biotech Kupando has raised an additional 10 million euros ($11 million), bringing its series A total to 23 million euros ($25 million), as it advances its lead candidate KUP101 into early-stage clinical testing. 18 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze